G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 27.4 PLN 3.01% Market Closed
Market Cap: 36.2m PLN
Have any thoughts about
Genomed SA?
Write Note
Section:
 

Relative Value

The Relative Value of one GEN stock under the Base Case scenario is 42.3 PLN. Compared to the current market price of 27.4 PLN, Genomed SA is Undervalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GEN Relative Value
Base Case
42.3 PLN
Undervaluation 35%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
85
vs Industry
82
Median 3Y
2.2
Median 5Y
2.3
Industry
7.6
More Details
41.3
P/E
P/E
Price to Earnings
41.3
vs History
75
vs Industry
3
Median 3Y
65.6
Median 5Y
66
Industry
21.3
More Details
19.8
P/OCF
P/OCF
Price to OCF
19.8
vs History
80
vs Industry
6
Median 3Y
29.6
Median 5Y
29
Industry
21.2
More Details
329.9
P/FCFE
P/FCFE
Price to FCFE
329.9
vs History
4
vs Industry
7
Median 3Y
34.2
Median 5Y
37.8
Industry
23.9
More Details
3.8
P/B
P/B
Price to Book Value
3.8
vs History
96
vs Industry
23
Median 3Y
5.1
Median 5Y
5.4
Industry
2.5
More Details
1.4
EV/S
EV/S
Enterprise Value to Sales
1.4
vs History
85
vs Industry
73
Median 3Y
2
Median 5Y
2.1
Industry
7.3
More Details
3.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.2
vs History
85
vs Industry
61
Median 3Y
5.2
Median 5Y
5.4
Industry
8.7
More Details
17.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.7
vs History
82
vs Industry
6
Median 3Y
25.7
Median 5Y
26.8
Industry
4.4
More Details
27.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
27.9
vs History
79
vs Industry
3
Median 3Y
44.4
Median 5Y
56.8
Industry
4.3
More Details
18
EV/OCF
EV/OCF
Enterprise Value to OCF
18
vs History
77
vs Industry
6
Median 3Y
27.4
Median 5Y
26.8
Industry
6
More Details
391.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
391.9
vs History
3
vs Industry
8
Median 3Y
31.2
Median 5Y
34.4
Industry
4
More Details
4.3
EV/IC
EV/IC
Enterprise Value to IC
4.3
vs History
96
vs Industry
33
Median 3Y
6.7
Median 5Y
7.1
Industry
4.4
More Details

Multiples Across Competitors

GEN Competitors Multiples
Genomed SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Genomed SA
WSE:GEN
36.2m PLN 1.6 41.3 17.7 27.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 722 085.5 -184 040.3 -223 483.5 -220 933.3
US
Abbvie Inc
NYSE:ABBV
309.5B USD 5.6 60.9 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
140.9B USD 4.3 33.3 16 30.3
US
Gilead Sciences Inc
NASDAQ:GILD
112B USD 4 888.8 9.8 9.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.6B USD 9.9 -220 21.7 22.8
US
Epizyme Inc
F:EPE
94.1B EUR 1 819.4 -464.2 -505.6 -492.1
AU
CSL Ltd
ASX:CSL
137.8B AUD 5.7 32.1 19.9 24.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.7B USD 5.5 16.5 14.9 16.6
US
Seagen Inc
F:SGT
39.3B EUR 17.5 -53.7 -57.7 -52.1
NL
argenx SE
XBRU:ARGX
38.5B EUR 18 -349.4 -166.3 -108.3
P/S Multiple
Revenue Growth P/S to Growth
PL
G
Genomed SA
WSE:GEN
Average P/S: 3 520 361.5
1.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
38 722 085.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
6%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.3
8%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
4
3%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
1 819.4
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
7%
0.8
US
S
Seagen Inc
F:SGT
17.5
30%
0.6
NL
argenx SE
XBRU:ARGX
18
53%
0.3
P/E Multiple
Earnings Growth PEG
PL
G
Genomed SA
WSE:GEN
Average P/E: 178.8
41.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -184 040.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
60.9
72%
0.8
US
Amgen Inc
NASDAQ:AMGN
33.3
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
888.8
21%
42.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -220
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -464.2 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -349.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
PL
G
Genomed SA
WSE:GEN
Average EV/EBITDA: 16.5
17.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -223 483.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.7
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.6 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.9
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -166.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
PL
G
Genomed SA
WSE:GEN
Average EV/EBIT: 22.2
27.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 933.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.3
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -492.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.7
16%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.3 N/A N/A

See Also

Summary
GEN intrinsic value, competitors valuation, and company profile.
DCF Valuation
GEN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GEN stock valuation using valuation multiples.
Wall Street Estimates
GEN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GEN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 216,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.